12 results about "Carcinoma cell line" patented technology

This invention discloses 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives, their synthesis methods and applications, belonging to the field of pharmaceutical technology, and involving two series of compounds: 3-sulfonamido-2'-hydroxy-4,4',6'-trimethoxychalcone and 8,3'-disulfonamido-5,7,4'-trimethoxyflavanone, and their preparation methods. Starting with 2-hydroxy-4,6-dimethoxyacetophenone and p-anisaldehyde or 4-methoxy-3-nitrobenzaldehyde, 2'-hydroxy-4,4',6'-trimethoxychalcone or 3-amino-2'-hydroxy-4,4',6'-trimethoxychalcone intermediates were synthesized via the Claisen-Schmidt reaction. Then, through sulfonation and intramolecular Michael addition reactions, 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives were synthesized. The preparation method is simple, mild, and yields high results. In vitro and in vivo activity tests show that the derivatives disclosed in this invention have significant in vitro inhibitory activity against gastric cancer, esophageal cancer, colorectal cancer, and lung cancer cell lines, acting as inhibitors of the protein YBX1 / RPN1. Clinically, they can be applied to targeted therapy for cancers such as gastric cancer, esophageal cancer, colorectal cancer, and lung cancer.

The invention provides a primary cell culture method for constructing a lung cancer cell line by using a micro-tumor PTC (Positive Temperature Coefficient) in-vitro model. PTC is a 3D tumor microsphere which is formed by performing digestion pretreatment on a tumor tissue from a patient and performing self-assembly again in an in-vitro liquid culture medium. The PTC micro-tumor comprises a plurality of cell types such as tumor cells, fibroblasts and immune cells derived from epithelium in original tissues, and has the advantages of short self-assembly period, high culture success rate and the like. The human-derived lung cancer cell line is constructed by utilizing PTC, so that the time cost can be shortened while bacterial pollution is reduced, the culture success rate is improved, and the characteristics and multiplication capacity of a primary lung cancer cell line are reserved.

The invention belongs to the technical field of tumor model construction, and discloses a lung adenocarcinoma animal model with high bone metastasis, a cell line and a construction method and application thereof. The lung adenocarcinoma animal model with high bone metastasis is provided through multi-generation in-vivo directional screening, and the construction method is efficient, controllable, high in repeatability, capable of remarkably improving the tumor formation efficiency and rate, capable of being applied to immune healthy mice, low in cost and high in stability. And further extracting tumor cells from the bone metastasis lesion of the animal model to obtain the mouse lung adenocarcinoma cell line with high bone metastasis. The cell line has the advantages of being excellent in bone metastasis performance, stable in phenotype, heritable and the like, can be connected with an existing research system, has universality and economical efficiency, and can efficiently meet the requirement of bone metastasis mechanism research on a high-specificity model. The method can be applied to the fields of construction of tumor animal models or cell lines of bone metastasis, screening or development of lung adenocarcinoma drugs and the like.

The application provides a synthesis method and antitumor application of several furanopyrimidine-ibuprofen hybrid derivatives, which are linked by aza-wittig reaction, intramolecular cyclization, substitution reaction, hydrolysis and acidification reaction and the like, and a fused triazole, a hydrazide, a bis-hydrazide and an oxadiazole are used as a bond bridge key, so that different series of furanopyrimidine-ibuprofen hybrid derivatives are synthesized in a simple and efficient manner. The CCK8 method in vitro pharmacodynamics test proves that the target compound has proliferation inhibition activity on A549 lung cancer cells and HepG2 liver cancer cell lines. Test results show that the target compound shows good proliferation inhibition activity on the two kinds of cells, and the structural formula is as follows:

The present invention relates to anticancer drug-resistant and sensitive liver cancer cell lines, and a method for screening liver cancer therapeutic agents by using same. Specifically, provided are a liver cancer cell line PLLC15 (Accession No. 00000) that does not have sorafenib resistance and / or a liver cancer cell line PLLC15_Sora (Accession No. 00000) that has sorafenib resistance, or a composition for screening anticancer agents including one or more thereof, and a method for screening anticancer agents, and thus an anticancer immunotherapeutic agent or method using immune function of an experimental animal can be screened and time and cost can be reduced by reviewing in advance a sorafenib resistance problem in the development stage of liver cancer therapeutic agents.

The invention discloses a reagent combination or a kit for preparing gamma delta T cells and application of the reagent combination or the kit. In the gamma delta T cell population obtained by the invention, most cells show CD4-CD8a-double negative phenotypes, part of the cells express CD56, and TCR alpha beta and CD41a are not expressed at all, which are consistent with the phenotypes of natural human gamma delta T cells. The gamma delta T cell obtained by the invention has the capability of secreting TNF-alpha and IL-2 cell factors. The gamma delta T cell obtained by the invention has a relatively strong cytotoxic effect on liver cancer cell lines, such as HepG2 cells and Huh-7 cells. The gamma delta T cells can effectively inhibit the proliferation of cancer cells, but have little influence on normal cells, and show high targeting and selectivity.

The invention discloses a macaque skin squamous carcinoma cell line MCSCC14397 and application of the macaque skin squamous carcinoma cell line MCSCC14397. The macaque skin squamous carcinoma cell line is named as macaque skin squamous carcinoma cell line MCSCC14397, and the preservation number of the macaque skin squamous carcinoma cell line is CCTCC (China Center For Type Culture Collection) NO: C2025156. The cell line disclosed by the invention has similar protein expression with primary tumor tissues, has chromosome abnormal karyotype, in-vitro tumor formation capability and stable proliferation characteristics, and simultaneously shows remarkable genome instability (such as high-frequency Cgt, T mutation and structural variation) and inflammation signal activation. The MYO10 gene expression in the cell line is up-regulated and drives DNA damage reaction and inflammatory factor expression, and unique advantages are provided for application of the cell line in skin squamous cell carcinoma mechanism research, drug screening and drug efficacy evaluation. The cell line disclosed by the invention can be used as an effective cell model, can be used for establishing a xenotransplantation animal model, and can provide a research basis for deeply researching the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous cell carcinoma as well as innovative drug development and screening.

The application discloses a rhesus monkey skin squamous carcinoma cell line MCSCC14397 and application thereof. The rhesus monkey skin squamous carcinoma cell line is named as the rhesus monkey skin squamous carcinoma cell line MCSCC14397, and the preservation number is CCTCC NO: C2025156. The cell line of the application has similar protein expression as primary tumor tissue, has abnormal karyotype, in-vitro tumorigenic ability and stable proliferation characteristics, and simultaneously shows significant genomic instability (such as high-frequency C>T mutation, structural variation) and inflammation signal activation. MYO10 gene expression is up-regulated in the cell line and drives DNA damage response and inflammation factor expression, which provides unique advantages for the application of the cell line in skin squamous carcinoma mechanism research, drug screening and efficacy evaluation. The cell line of the application can be used as an effective cell model, can establish a xenotransplantation animal model, and can provide a research basis for in-depth research on the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous carcinoma and innovative drug development and screening.

The invention relates to the technical field of biological medicines, in particular to application of an IFI27 gene as a liver cancer treatment target. It is found for the first time that IFI27 is remarkably up-regulated in liver cancer tissue, the expression level of IFI27 in paracancerous normal tissue is low, good tumor specificity is shown, and it is indicated that IFI27 plays an important role in liver cancer progression. Furthermore, an in-vitro cell experiment proves that the proliferation activity, the clone forming ability and the migration invasion ability of a liver cancer cell line can be remarkably inhibited by knocking down IFI27 expression through shRNA, and powerful evidence is provided for taking the IFI27 gene as a liver cancer treatment target. It is further verified that the growth of liver tumors can be effectively inhibited by knocking down IFI27 expression in an animal body. In conclusion, the IFI27 can be used as a potential new target for targeted therapy of the liver cancer, and a small-molecule inhibitor or a biological preparation aiming at the IFI27 has research value and clinical transformation potential for being developed into an innovative medicine for the liver cancer. The invention provides a new theoretical basis and an intervention strategy for precise treatment of liver cancer.

An Umbilical cord derived mesenchymal stem cell (UC-MSC) conditioned media (UC- MSC-CM) composition of the range from 5%-100% possessing immunomodulatory effect inhibiting tumour growth when administered intraperitoneally and intravenously. MSC- CM arrests cell cycle in leukaemia cells (K-562 and HL-60), lung cancer cells (A549 and HOP-62), breast cancer cells (MDA-MB-231 and MCF-7) and cervical cancer cells (HeLa). Elevated levels of IL-6, TIM3 and TIMP2 in MSC-CM confer to its immunomodulatory function by leading to an increase in expression of activation markers, cytotoxic granules, mucosal associated invariant T cells and decreasing the inflammasome pathway activation, consequently decreasing the levels of innate immune inflammasome pathway molecules in treated xenograft tumor tissues. MSC-CM as an adjunct with IL-12 augments cytotoxic potential against cancer cell lines. Tumor inhibition effect of MSC-CM is shown by significant reduction of relative tumor volume which is expressed by fold change of genes involved in various pathways affecting xenograft tumor growth.

The invention belongs to the technical field of biological medicine, and discloses a carbazole compound embedded with a boron-nitrogen unit, and a synthesis method and application thereof, the carbazole compound has a structure of a general formula (I): (A)-(L)-(B), including isomers or pharmaceutically acceptable salts thereof. The synthesis method of the compound is simple and convenient to operate, mild in condition and wide in substrate applicability. The PARP14 inhibitor GeA-69 is subjected to BN modification through the method, and the obtained compounds G-1 and G-2 have low toxicity to normal cells HEK-293 (human kidney epithelial cell line) while keeping the inhibitory activity to tumor cells such as HeLa cells (cervical cancer cell line) and the like. The invention provides a new strategy for development of new drugs based on a carbazole structure.

This invention discloses the application of SLC10A3 as a target in the preparation of drugs for the prevention and / or treatment of gastric cancer, belonging to the field of biomedical technology. This invention discovers that the small interfering RNA of SLC10A3 exerts an anti-tumor effect by inhibiting the proliferation, invasion, and migration of gastric cancer cells and promoting ferroptosis. Inhibiting endogenous SLC10A3 in the SGC-7901 gastric cancer cell line can inhibit the proliferation, invasion, and migration of gastric cancer cells and promote ferroptosis. Combining the small interfering RNA of SLC10A3 with a suitable carrier to form a drug, and introducing it into gastric tissue or the body, will have preventive and therapeutic effects on gastric cancer. It is hoped that the small interfering RNA of SLC10A3 can be combined with chitosan, cholesterol, liposomes, nanoparticles, etc., to form drug molecules for the prevention and treatment of gastric cancer via oral, intravenous, intramuscular, or direct intragastric injection.